Saturday, September 12, 2026

The Silent Impact of Domestic Violence: Early Onset of Menopause

A recent study has found that women...

93 Years of Resistance: Pyongyang Swaps Tanks for Ideology

North Korea commemorates the 93rd anniversary of the Korean People's Revolutionary Army with rising enthusiasm for anti-Japanese sites.

Blitzkrieg Delivery: South Korea Floods Europe With K2 Tanks, Shattering Supply Chains

Hyundai Rotem expands globally with its K2 tank, showcasing advanced defense tech and unmanned vehicles at Seoul ADEX 2025.

Tag: SK Biopharmaceuticals

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

SK Biopharmaceuticals Acquires Opacalim: What This 795 Million USD Epilepsy Drug Deal Means for Patients

SK Biopharmaceuticals has acquired a new epilepsy drug candidate from Biohaven Bioscience, enhancing its portfolio in neurology.

SK Biopharmaceuticals Launches U.S. Innovation Hub to Help Korean Biotechs Expand Globally

SK Biopharmaceuticals launched SK Life Science LinX to support Korean biotech firms entering the U.S. market, fostering innovation and collaboration.

SK Biopharmaceuticals Unveils Breakthrough Findings on NTSR1-Targeted Radiopharmaceutical SKL35501

SK Biopharmaceuticals will present findings on NTSR1-targeted treatments at the AACR Annual Meeting, showcasing innovative oncology research.

SK Biopharmaceuticals Selects Two CNS Startups Through Open Innovation… Advances Expected in Parkinson’s and Alzheimer’s Treatment

SK Biopharmaceuticals partners with Seoul Bio Hub to support two CNS startups, Novorex and Threebrooks, in innovative drug development.

Exploring Cenobamate: How SK Biopharmaceuticals’ New Oral Suspension Benefits Adult Epilepsy Patients

SK Biopharmaceuticals submits NDA for Cenobamate oral suspension, enhancing treatment options for epilepsy patients with swallowing difficulties.

SK Biofarm, FDA Approved Radioactive Method: Will it be a Revolutionary Cancer Cure with SLK 33501?

SK Biopharmaceuticals gains FDA approval for Phase 1 trials of radiopharmaceuticals SKL35501 and SKL35502, advancing cancer treatment.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.